Magnesium glycerophosphate oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of magnesium glycerophosphate.
Treatment of chronic magnesium deficiency or hypomagnesaemia.
Treatment of hypomagnesaemia in adult patients due to the concomitant administration of loop and thiazide diuretics or other drugs.
Dosage regimen should be adjusted according to individual serum total magnesium level.
4mmol to 8mmol (1 to 2 tablets) three times a day.
Children aged 12 to 18 years: 4mmol (1 tablet) three times a day.
Children aged 4 to 12 years: 4mmol (1 tablet) twice a day.
The following alternative dosing schedule may be suitable:
Children aged 12 to 18 years: 4mmol to 8mmol three times a day (unlicensed).
Children aged 1 month to 12 years: 0.2mmol/kg three times a day (unlicensed).
Severe renal impairment
Precautions and Warnings
Children aged 1 month to 4 years
Glucose-galactose malabsorption syndrome
Hereditary fructose intolerance
Small bowel resection
Some formulations contain aspartame - caution in phenylketonuria
Correct hypocalcaemia before or during treatment
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Some formulations contain sucrose
Advise patient not to take other medicines within 2 hours
Correct hypokalaemia before or during treatment
Monitor serum magnesium regularly
Pregnancy and Lactation
Use magnesium glycerophosphate with caution during pregnancy.
The manufacturer recommends magnesium glycerophosphate is not used in pregnancy unless the benefits outweigh any potential risks.
Available data following use in human pregnancy does not indicate an increased risk of teratogenic or developmental effects.
Magnesium glycerophosphate is considered safe for use during breastfeeding.
Manufacturers advise magnesium glycerophosphate may be use during breastfeeding.
Magnesium glycerophosphate and its metabolites are excreted in human milk but at normal doses the effects are not considered to be clinically significant.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: April 2020
Summary of Product Characteristics: Magnesium 4mmol Chewable Tablets. Colonis Pharma Ltd. Revised November 2019.
Summary of Product Characteristics: Neomag 4mmol Chewable Tablets. Neoceuticals Limited. Revised January 2017.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 16 April 2020
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.